HOME >> BIOLOGY >> NEWS
JCI Table of Contents, March 14, 2003

ard@cochin.inserm.fr">boitard@cochin.inserm.fr

View the PDF of this article at: https://www.the-jci.org/press/16584.pdf

Cathepsin S promotes atherosclerosis

Remodeling of the ECM contributes to atherosclerosis at multiple stages, and several lines of evidence have implicated the elastolytic cathepsins S (Cat S) and K. Seeking direct evidence for a role of Cat S, Guo-Ping Shi and colleagues crossed mice lacking Cat S with atherosclerosis-prone LDL receptordeficient mice. They found (pages 897906) that the double mutants -- when fed a high-cholesterol diet -- had an attenuated response: atherosclerosis was reduced by more than 50% after 12 weeks on an atherogenic diet, and by 30% after 26 weeks. While this study does not reveal the mechanism by which Cat S contributes to atherogenesis, it does suggest several possible modes of action and underscores the possibility that Cat S may serve as a therapeutic target in arterial diseases.

CONTACT:
Guo-Ping Shi
University of California, San Francisco
Surge 203, Box 0911
90 Medical Center Way
San Francisco, CA 94143
USA
Phone 1-415-514-1208
Fax 1-415-476-9749
E-mail: gpshi@itsa.ucsf.edu

View the PDF of this article at: https://www.the-jci.org/press/14915.pdf

Stem cells mobilized by crisis

Sickle cell disease affects 150 million people worldwide. The only curative therapy is hematopoietic stem cell transplantation. Because of the limited number of matched donors and the toxicity associated with allogeneic transplants, various gene therapy approaches in autologous stem cells are under development. Encouraged by the observation that sickle cell patients have increased numbers of cells expressing stem
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
14-Mar-2003


Page: 1 2 3 4 5 6 7

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, 1 October, 2003
5. JCI Table of Contents, September 15, 2003
6. JCI Table of Contents
7. JCI Table of Contents, 15 August 2003
8. JCI Table of Contents, May 1, 2003
9. JCI Table of Contents, April 1, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... PARSIPPANY, N.J. , Jan. 20, 2017 /PRNewswire/ ... the "Company"), a company that provides clinically useful ... that it has entered into a securities purchase ... aggregate of 855,000 shares of common stock in ... placement, the Company has agreed to sell to ...
(Date:1/21/2017)... 20, 2017 Aratana Therapeutics, Inc. (NASDAQ: ... the licensing, development and commercialization of innovative biopharmaceutical products ... Company in North America 2016. ... based on the FDA approval of three innovative ... ® (capromorelin oral solution) and NOCITA ® ...
(Date:1/20/2017)... ... 2017 , ... The two newest companies to join the University City Science ... out from The Wistar Institute, and Sanguis, launched by a trio of students from ... , Vironika is developing a treatment for a chronic viral infection and its associated ...
(Date:1/20/2017)... 20, 2017 Ginkgo Bioworks, the organism ... pioneer in the synthesis and assembly of DNA. ... assembling pathway-length synthetic DNA into Ginkgo,s automated organism ... the construction of new organism designs for application ... "Gen9 was founded to significantly increase the world,s ...
Breaking Biology Technology:
Cached News: